Antibody-drug conjugate · Cytotoxic, directed at glypican 3 (GPC3) · developed by Zymeworks BC
ZW251 is an antibody-drug conjugate composed of a humanized IgG1 monoclonal antibody targeting glypican 3 conjugated to ZD06519, a camptothecin-based topoisomerase 1 inhibitor. Upon binding to GPC3 on tumor cells, the antibody delivers ZD06519, which inhibits topoisomerase 1 activity, causing DNA strand breaks, cell cycle arrest, and apoptosis. It is studied in hepatocellular carcinoma, squamous cell non-small cell lung cancer, and germ cell tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07164313 | Phase 1 | Hepatocellular Carcinoma | Recruiting | ZYME |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Germ Cell TumorHepatocellular CarcinomaSquamous Cell Non-Small Cell Lung Cancer
Updated Oct 3, 2026. Something wrong or missing? Report it on the ZYME page.
See ZYME's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ZYME catalysts and pipeline →